Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Urolithiasis ; 52(1): 98, 2024 Jun 22.
Article in English | MEDLINE | ID: mdl-38907797

ABSTRACT

Urolithiasis is a common disease that affects approximately one-fifth of the global population. This systematic review explores the predictive role of inflammatory markers for the spontaneous passage of ureteral stones. The literature was systematically searched via Google Scholar, PubMed/MEDLINE, the Cochrane Library, Science Direct, CINAHL, Web of Science, and EMBASE databases to identify papers published until 2023. Overall, 26 articles were identified, of which 10 were excluded. The remaining 16 papers reported 2,695 patients (1,723 males and 972 females), with 1,654 (61.37%) experiencing spontaneous stone passage (SSP) and 1,041 (38.63%) not experiencing it (non-SSP). Stones located in the upper part of the ureter were less likely to pass spontaneously (152/959, 15.94% in the SSP group vs. 180/546, 32.48% in the non-SSP group; p < 0.001). Mid-ureteral stones were present in 180/959 (18.75%) of the SSP group compared to 84/546 (14.52%) of the non-SSP group (p = 0.0974). Lower ureteral stones were more likely to pass spontaneously, with 627/959 (63.31%) in the SSP group compared to 282/546 (49.36%) in the non-SSP group (p < 0.001). No significant correlation was found between most inflammatory markers and SSP (p > 0.05). However, procalcitonin levels were lower in the SSP group compared to the non-SSP group (132.7 ± 28.1 vs. 207 ± 145.1, respectively) (p < 0.001). This systematic review has revealed that except procalcitonin, most inflammatory markers do not offer significant predictive capability for ureteral SSP.


Subject(s)
Biomarkers , Predictive Value of Tests , Ureteral Calculi , Humans , Ureteral Calculi/blood , Biomarkers/blood , Biomarkers/analysis , Remission, Spontaneous , Inflammation/blood
2.
Med Int (Lond) ; 3(5): 51, 2023.
Article in English | MEDLINE | ID: mdl-37810904

ABSTRACT

Spermatocytic tumors are a rare type of testicular cancer, comprising <1% of all testicular malignancies. This type of cancer typically affects males in their 60s and 70s and rarely metastasizes; however, it poses a threat to the health of affected individuals if left untreated. The present study describes the case of a 68-year-old male patient with this type of tumor, including a presentation of his initial symptoms, treatment and subsequent monitoring. A male patient, aged 68 years, visited the authors' clinic with an asymptomatic mass in the right testicle. The mass had been progressively increasing in size for a duration of 5 years following a history of blunt injury. During the examination, a noticeable, painless enlargement was detected in the right testis, whereas the left testis appeared to be in a normal state. Tumor markers were within normal limits. Imaging revealed a complex mass (11x8x7 cm) almost replacing the right testis, with no detectable lymph nodes. A right radical orchidectomy was performed under spinal anesthesia. A histopathological examination revealed a spermatocytic tumor. The post-operative period was uneventful, with no metastasis detected in the CT scans. The patient was discharged with instructions for regular follow-up appointments. The case presented herein highlights a rare spermatocytic tumor in a 68-year-old male. The early detection and treatment of testicular tumors, regardless of age, are crucial for a good prognosis.

3.
Med Int (Lond) ; 3(3): 31, 2023.
Article in English | MEDLINE | ID: mdl-37359054

ABSTRACT

Subcutaneous metastasis from esophageal cancer (EC), particularly to the chest wall, is a very rare phenomenon. The present study describes a case of gastroesophageal adenocarcinoma that metastasized to the chest wall, invading the fourth anterior rib. A 70-year-old female presented with acute chest pain 4 months after undergoing Ivor-Lewis esophagectomy for gastroesophageal adenocarcinoma. A chest ultrasound revealed a solid hypoechoic mass on the right side of the chest. A contrast-enhanced computed tomography scan of the chest revealed a destructive mass on the right anterior fourth rib (7.5x5 cm). Fine needle aspiration revealed a metastatic moderately differentiated adenocarcinoma to the chest wall. Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography revealed a large FDG avid deposit on the right side of the chest wall. Under general anesthesia, a right-side anterior chest incision was made and the second, third and fourth ribs were resected with overlying soft tissues, including the pectoralis muscle and overlying skin. The histopathological examination confirmed a metastasized gastroesophageal adenocarcinoma to the chest wall. There are two common assumptions regarding chest wall metastasis from EC. The first one states that this metastasis can occur due to the implantation of the carcinoma during tumor resection. The latter supports the notion of tumor cell dissemination along the esophageal lymphatic and hematogenous systems. Chest wall metastasis from EC invading ribs is an extremely rare incident. However, its likelihood of occurrence should not be neglected following primary cancer treatment.

4.
Med Int (Lond) ; 3(3): 22, 2023.
Article in English | MEDLINE | ID: mdl-37214230

ABSTRACT

Synovial sarcoma is a mesenchymal spindle cell tumor. Primary pancreatic sarcomas are extremely rare. The present study describes a rare case of synovial sarcoma in the head of the pancreas. A 35-year-old male presented with left upper quadrant abdominal pain. An endoscopic ultrasound examination revealed a complex solid-cystic lesion in the pancreatic head. He had undergone pancreaticoduodenectomy (Whipple procedure). A histological examination yielded negative results for AE1/AE3, CD10, S100, CD34, desmin, smooth muscle actin, ß-catenin, CD117, HMB45, chromogranin and synaptophysin. However, the results were positive for TLEI and vimentin, which is consistent with synovial sarcoma. Synovial sarcoma is a soft tissue malignant tumor. Primary pancreatic sarcomas frequently present as large, high-grade tumors in the pancreatic head. Histologically, there are several types of synovial sarcoma, such as monophasic, biphasic and poorly differentiated. A histological examination is necessary for the diagnosis as the imaging findings are not specifically suggestive of synovial sarcoma. The preferred course of treatment is complete resection with wide margins, followed by adjuvant chemotherapy and/or radiotherapy. Primary mesenchymal tumors of the pancreas are extremely uncommon. As a result, a diagnosis requires careful evaluation. Surgical resection is the main modality of treatment.

5.
Pharm Dev Technol ; 26(3): 262-268, 2021 Mar.
Article in English | MEDLINE | ID: mdl-33307914

ABSTRACT

Self-emulsifying lipids (SEL) were used as a stabilizer for the preparation of dexamethasone lipid nanoparticles by membrane emulsification employing Shirasu porous glass. The effect of process and formulation parameters on the size and polydispersity and dexamethasone solubility in lipids and its release from lipid nanoparticles were investigated. Lipid phase pressure (40-80 kPa), membrane pore-size (0.1 - 0.4 µm) and agitation speed (300 - 900 rpm) did not affect the size and polydispersity of SEL. However, the size was increased with increasing lipid content and fatty acid chain of the lipid. Sizes of < 250 nm were achieved from TEGO® care:Gelucire® blend and it increased to 487 nm by adding 20% w/w of hard fat. The highest solubility of dexamethasone was found in TEGO® care 450 (29 mg/g). Release from the lipid nano-dispersions was extended with no burst effect and the absolute release was increased with increasing lipid content.


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Dexamethasone/administration & dosage , Drug Carriers/chemistry , Emulsifying Agents/chemistry , Lipids/chemistry , Anti-Inflammatory Agents/chemistry , Dexamethasone/chemistry , Excipients/chemistry , Nanoparticles/chemistry
6.
Pharm Dev Technol ; 25(6): 729-734, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32125213

ABSTRACT

The objective of this study was to investigate cellulose acetate butyrate (CAB) as a carrier for extended-release alcohol-resistant matrix tablet. Powder blends were either directly compressed or granulated before compression. The drug release from CAB matrix tablet was robust to formulation/process parameters such as compression force (10-20 kN), granular size (0.15-1.40 mm), and drug content (50-70%). In addition, release medium variables such as ionic strength, pH, and agitation rate had no effect on the drug release. CAB matrix tablet was more robust than ethylcellulose matrix tablet; the release from CAB matrix tablet was not affected by ethanol content (up to 20% v/v) in the release medium irrespective of agitation. CAB is a promising polymer for formulating of alcohol-resistant extended-release matrix tablet.


Subject(s)
Cellulose/analogs & derivatives , Drug Carriers/chemical synthesis , Drug Carriers/pharmacokinetics , Drug Liberation , Ethanol/chemical synthesis , Ethanol/pharmacokinetics , Cellulose/chemical synthesis , Cellulose/pharmacokinetics , Tablets
7.
Int J Pharm ; 577: 119050, 2020 Mar 15.
Article in English | MEDLINE | ID: mdl-31991186

ABSTRACT

The aim of this work was to develop a mathematical model to estimate the drug release from a conventional single-compartment reservoir pellet and extend its applicability to multi-compartment reservoir pellets. Conventional pellets were prepared by layering the drug onto starter-core then applying various ethylcellulose/HPC coatings for drug release control. Multi-layered pellets comprised a first drug layer of propranolol HCl (D1) followed by a first controlled release coating (C1) and consecutively a second drug layer of carbamazepine or caffeine (D2) and then a second controlled-release coating (C2). Drug release from single- and multi-compartment pellets generally increased with an increase of the water-soluble HPC in the coatings. The response described a sigmoidal curve, which agreed with a cumulative normal distribution function. The developed mathematical model facilitated quantification of the drug release of pellets as a function of the porogen content and the coating level. Additionally, the model was applied successfully in multi-compartment pellets to calculate theses effects on the release of drugs with a broad range of aqueous solubility.


Subject(s)
Cellulose/analogs & derivatives , Drug Carriers/chemistry , Models, Theoretical , Caffeine/administration & dosage , Caffeine/chemistry , Carbamazepine/administration & dosage , Carbamazepine/chemistry , Cellulose/chemistry , Chemistry, Pharmaceutical , Delayed-Action Preparations , Drug Liberation , Porosity , Propranolol/administration & dosage , Propranolol/chemistry , Solubility , Water/chemistry
8.
Biomed Res Int ; 2019: 3619357, 2019.
Article in English | MEDLINE | ID: mdl-31781612

ABSTRACT

OBJECTIVE: The present study aims at evaluating the beneficial effect of Nigella sativa (NS) oil mouth rinse in the management of chemotherapy- (CT-) induced oral mucositis (OM) in patients with acute myeloid leukemia (AML). METHODS: Fifty-four AML patients were participated in this study and randomly allocated to either the test group or a control group. The patients of the test group received NS oil mouth rinse during 28-day CT, while the participants of the control group received a "magic mouthwash" formula. The primary outcome of this study was the incidence and severity of CT-induced OM in terms of erythema and ulcer. The secondary outcomes were the pain severity score, swallowing function, and the salivary concentrations of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). RESULTS: NS oil mouth rinse attenuated the progression of CT-induced OM compared with the control formula (AUC = 5.9 vs. 38.4, P < 0.05) and significantly decreased the erythema and ulceration scores (AUC of total OMAS = 11.4 vs. 85.9, P < 0.001) compared with the magic mouthwash formula. It also reduced the pain score and enabled all the participants of this group to consume normal food during treatment. It significantly decreased salivary IL-6 (AUC = 7376 vs. 16599, P < 0.001), while the changes of TNF-α levels were not significant (AUC = 676.9 vs. 885.2, P > 0.05). CONCLUSIONS: NS oil mouth rinse is effective in attenuating the severity of CT-induced OM and improves the pain and swallowing function in AML patients.


Subject(s)
Leukemia, Myeloid, Acute/drug therapy , Nigella sativa/chemistry , Plant Oils/administration & dosage , Stomatitis/therapy , Adult , Female , Gene Expression Regulation, Neoplastic/drug effects , Humans , Interleukin-6/genetics , Leukemia, Myeloid, Acute/complications , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/pathology , Male , Middle Aged , Mouthwashes/therapeutic use , Plant Oils/chemistry , Stomatitis/chemically induced , Tumor Necrosis Factor-alpha/genetics
9.
Int J Pharm ; 569: 118520, 2019 Oct 05.
Article in English | MEDLINE | ID: mdl-31362093

ABSTRACT

The objective of this study was to investigate the applicability of water-insoluble polymers as binders for pellet drug layering to extend the drug release. Carbamazepine was layered on sugar cores in fluidized bed coater using isopropanol (IPA):water solution or aqueous dispersion of ethylcellulose, polyvinyl acetate or ammonium-methylmethacrylate copolymer. Carbamazepine release was extended with all investigated water-insoluble polymers used as binder, without an additional coating layer. Drug release from pellets layered using IPA:water polymer solutions was dependent on polymer properties such as lipophilicity and pore-forming components, while from those layered with aqueous polymer dispersions, the release was dependent on the completeness of film formation during drug layering. Curing effect was observed only for pellets layered with Aquacoat® ECD and Eudragit® RS 30D. The drug release was not affected by compression when pellets were prepared with the flexible polymers Kollidon® SR or Kollicoat® SR 30D, however, it increased when brittle polymers such as ethylcellulose or Eudragit® RS were used. This problem could be minimized by using a higher amount of the binder, addition of a plasticizer or using polymers of higher viscosity grade. In conclusion, the use of water-insoluble polymers as binder for pellet drug layering is an effective tool to extend the drug release without additional coating step.


Subject(s)
Cellulose/analogs & derivatives , Drug Compounding/methods , Polymethacrylic Acids/chemistry , Polyvinyls/chemistry , 2-Propanol/chemistry , Carbamazepine/chemistry , Cellulose/chemistry , Drug Liberation , Excipients/chemistry , Solubility , Water/chemistry
10.
AAPS PharmSciTech ; 20(4): 142, 2019 Mar 14.
Article in English | MEDLINE | ID: mdl-30874996

ABSTRACT

The objective of this study was to modify the release of two drugs having different solubility in a combined matrix tablet as a fixed-dose combination for extended release. Propranolol HCl (freely soluble) and carbamazepine (very slightly soluble) were used as model drugs, water-soluble hydroxypropyl methylcellulose (HPMC) and water-insoluble ethylcellulose (EC) were used as matrix-forming polymers. Tablets were prepared by direct compression of powder blends, or propranolol HCl was first granulated with one of the matrix-forming polymers (1:1) followed by compression with carbamazepine and matrix former. Propranolol HCl release from directly compressed tablets was faster than carbamazepine because of its higher solubility. The release of both drugs was fast when HPMC-propranolol HCl granules were compressed with carbamazepine into EC matrix tablet. Conversely, the release of both drugs was decreased when HPMC-propranolol HCl granules and carbamazepine were compressed into HPMC matrices. The desired release of both drugs was approached when EC-propranolol HCl granules were compressed with carbamazepine into HPMC matrix. Erosion of the HPMC matrix and, therefore, drug release were adjusted by varying the molecular weight of HPMC. A burst release of propranolol HCl decreased when it was granulated with EC in a fluidized bed coater followed by compression with carbamazepine into HPMC matrix.


Subject(s)
Adrenergic beta-Antagonists/chemistry , Anticonvulsants/chemistry , Carbamazepine/pharmacokinetics , Propranolol/pharmacokinetics , Carbamazepine/chemistry , Cellulose/analogs & derivatives , Cellulose/chemistry , Hypromellose Derivatives/chemistry , Propranolol/chemistry , Solubility , Tablets
SELECTION OF CITATIONS
SEARCH DETAIL
...